Unlocking manufacturing capacity will be key for Legend Biotech and Johnson and Johnson in achieving their goal of reaching ...

Trump admin's FDA medical product review units remain protected from cuts, while Marty Makary awaits confirmation as ...

Ono Pharmaceuticals is spending $280 million upfront to take the global rights of Ionis Pharmaceuticals’ asset for a rare ...

Can Gilead be held accountable for holding back the sale of an HIV drug it allegedly knew was safer than its blockbuster predecessor? The answer could offer a unique example of a situation where a ...

Ascletis' ASC47 shows 1.7% weight loss vs. placebo in Phase 1b trial, Vivace gets a $35M Series D for VT3989, and Harbour BioMed launches obesity startup Élancé Therapeutics.

Viking Therapeutics has contracted CDMO CordenPharma for a total of $150 million to make billions of clinical and commercial doses of its GLP-1/GIP receptor agonist for weight loss.

Zealand Pharma partners with Roche on obesity drug petrelintide in $5.3B deal. Roche pays $1.4B upfront, plans combo studies with CT-388. Companies to split revenues in US/Europe.

Gilead said two experimental once-a-year versions of its HIV prevention shot lenacapavir passed muster in an early-stage ...

Merck has opened a new vaccine manufacturing plant at its existing site in Durham, NC, which will make a shot that is an ...

Bristol Myers Squibb will acquire its CAR-T cell therapy collaborator 2seventy bio for $286 million in cash, the companies ...

Arvinas/Pfizer's vepdegestrant shows efficacy in mutated breast cancer patients but not in broader population, failing to ...

Merck convinced a federal judge to toss claims alleging that it failed to properly warn patients of potential risks related ...